步长制药公告，全资子公司陕西步长高新制药有限公司近日收到国家药品监督管理局核准签发的磷酸奥 司他韦胶囊《药品注册证书》。该药品主要用于成人和1岁及以上儿童的甲型和乙型流感治疗，以及成 人和13岁及以上青少年的甲型和乙型流感预防。2022年至2024年中国城市实体药店年度销售额分别为 1.52亿元、8.24亿元和7.76亿元。截至公告披露日，公司在该项目上已投入研发费用约1296.12万元。 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.36% on August 28, with Xintian Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3843.6, up 1.14%, while the Shenzhen Component Index closed at 12571.37, up 2.25% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - Buchang Pharmaceutical (603858) with a closing price of 20.02, up 5.59% and a trading volume of 325,000 shares, totaling 654 million yuan [1] - Tianmu Pharmaceutical (600671) closed at 20.40, up 5.37% with a trading volume of 159,300 shares, totaling 324 million yuan [1] - Jilin Aodong (000623) closed at 20.34, up 1.75% with a trading volume of 239,000 shares, totaling 479 million yuan [1] - Conversely, significant decliners included: - Xinda Pharmaceutical (002873) with a closing price of 12.00, down 4.76% and a trading volume of 304,000 shares, totaling 364 million yuan [2] - Qidi Pharmaceutical (000590) closed at 12.22, down 4.61% with a trading volume of 221,600 shares, totaling 274 million yuan [2] - Kangjia Pharmaceutical (600557) closed at 17.22, down 4.39% with a trading volume of 313,700 shares, totaling 537 million yuan [2] Capital Flow - The Chinese medicine sector saw a net outflow of 1.134 billion yuan from institutional investors, while retail investors contributed a net inflow of 930 million yuan [2] - Key stocks with significant capital flow included: - Zhendong Pharmaceutical (300158) with a net inflow of 67.58 million yuan from institutional investors [3] - Jilin Aodong (000623) with a net inflow of 13.62 million yuan from institutional investors [3] - Tianmu Pharmaceutical (600671) with a net inflow of 7.33 million yuan from institutional investors [3]

按申万行业统计，步长制药所属的医药生物行业共有49家公司公布了2025半年度分配方案，派现金额最 多的是药明康德，派现金额为10.03亿元，其次是东阿阿胶、华润三九，派现金额分别为8.17亿元、7.51 亿元。（数据宝） 2025半年度医药生物行业分红排名 | 代码 | 简称 | 每10股送转 | 每10股派现 | 派现金额（万 | 派现占净利润比例 | 股息率 | | --- | --- | --- | --- | --- | --- | --- | | | | （股） | （元） | 元） | （%） | （%） | 8月27日步长制药发布2025半年度分配预案，拟10派3.9元（含税），预计派现金额合计为4.11亿元。派 现额占净利润比例为65.52%，以该股2025半年度成交均价计算，股息率为2.52%。这是公司上市以来， 累计第9次派现。 公司上市以来历次分配方案一览 | 日期 | 分配方案 | 派现金额合计（亿元） | 股息率（%） | | --- | --- | --- | --- | | 2025.06.30 | 10派3.9元（含税） | 4.11 | 2.52 | | 2023.12.31 ...

Group 1 - The company reported a revenue of 5,663,836,253.89 yuan for the first half of 2025, representing a year-on-year growth of 4.27% [1] - The net profit attributable to shareholders of the listed company was 627,701,257.33 yuan, showing a significant year-on-year increase of 171.24% [1]

Core Viewpoint - The company, Buchang Pharmaceutical, announced the approval of several proposals, including the 2025 semi-annual report and summary, during the 30th meeting of its fifth board of directors [2] Group 1 - The company held its fifth board of directors' 30th meeting on August 27 [2] - The meeting resulted in the approval of the 2025 semi-annual report and summary [2]

证券日报网讯 8月27日晚间，步长制药发布公告称，公司第五届监事会第七次会议审议通过了《关于公 司2025年半年度报告及摘要的议案》等多项议案。 （文章来源：证券日报） ...

Core Insights - The company reported a revenue of 5.664 billion yuan for the first half of 2025, representing a year-on-year growth of 4.27% [1][2] - The net profit attributable to shareholders reached 627 million yuan, showing a significant increase of 171.24% compared to the same period last year [1][2] - The net cash flow from operating activities was 959 million yuan, reflecting a growth of 92.87% year-on-year [1][2] Financial Performance - Revenue for the first half of 2025: 5.664 billion yuan, up 4.27% from 5.432 billion yuan in the same period last year [2] - Total profit for the period was approximately 750 million yuan, an increase of 85.55% from around 404 million yuan [2] - Net profit attributable to shareholders: 627 million yuan, up from 231 million yuan, marking a 171.24% increase [2] - Net profit after deducting non-recurring gains and losses: 619 million yuan, up 180.04% from 221 million yuan [2] - Net cash flow from operating activities: 959 million yuan, compared to 497 million yuan last year, a growth of 92.87% [2] Asset and Equity Position - Net assets attributable to shareholders at the end of the reporting period were approximately 10.744 billion yuan, a 5.16% increase from 10.216 billion yuan at the end of the previous year [2] - Total assets amounted to about 19.977 billion yuan, reflecting a 3.35% increase from 19.329 billion yuan [2] Leadership Information - Zhao Chao, the company's president, holds a PhD in economics from Xi'an Jiaotong University and has been in various leadership roles within the company [3] - Zhao Chao's compensation from 2020 to 2024 has been relatively stable, with figures around 231.1 thousand yuan in 2024 [4]

北京商报讯（记者 王寅浩 实习记者 宋雨盈）8月27日，步长制药发布公告称，2025年上半年实现营业 收入56.64亿元，同比增长4.27%；归属于上市公司股东的净利润为6.28亿元，同比增长171.24%；归属 于上市公司股东的扣除非经常性损益的净利润为6.19亿元，同比增长180.04%。 ...

山东步长制药股份有限公司 证券代码：603858 证券简称：步长制药 公告编号：2025-157 （一）董事会审议情况 公司于 2025 年 8 月 27 日召开第五届董事会第三十次会议，审议通过了《关 于公司 2025 年半年度利润分配的议案》，根据 2024 年年度股东会的授权，本次 利润分配方案无需提交公司股东会审议。 （二）监事会审议情况 公司于 2025 年 8 月 27 日召开第五届监事会第七次会议，审议通过了《关于 公司 2025 年半年度利润分配的议案》，同意公司 2025 年半年度利润分配方案。 认为本次利润分配方案符合相关法律、法规的要求及《山东步长制药股份有限公 司章程》的相关规定，不存在损害公司及其他股东、特别是中小股东利益的情形， 符合公司发展需求。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 一、利润分配方案内容 根据山东步长制药股份有限公司（以下简称"公司"）2025 年半年度报告（未 经 审 计 ）， 截 至 2025 年 6 月 30 日 ， 母 公 司 期 末 未 分 配 ...

证券代码：603858 证券简称：步长制药 公告编号：2025-155 山东步长制药股份有限公司 第五届董事会第三十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东步长制药股份有限公司（以下简称"公司"）第五届董事会第三十次会 议的通知于 2025 年 8 月 15 日发出，会议于 2025 年 8 月 27 日 13 时以通讯方式 召开，应参会董事 9 人，实参会董事 9 人，会议由董事长赵涛先生主持。会议出 席人数、召开和表决方式符合《中华人民共和国公司法》等法律、法规及《山东 步长制药股份有限公司章程》 （以下简称"《公司章程》"）的相关规定，合法有效。 经与会董事研究，会议审议通过了如下议案： 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《山 东步长制药股份有限公司 2025 年半年度报告》与《山东步长制药股份有限公司 表决结果：同意 9 票，反对 0 票，弃权 0 票。 本议案已经公司董事会审计委员会审议通过，同意提交董事会审议。 《关于公司 2025 年半年度募 ...